Advanced search
Publication Cover
Leukemia & Lymphoma Volume 45, 2004 - Issue 11
Submit an article Journal homepage
100
Views
55
CrossRef citations to date
0
Altmetric
Research Article

A Pilot Trial of Rituximab and Alemtuzumab Combination Therapy in Patients with Relapsed and/or Refractory Chronic Lymphocytic Leukemia (CLL)

Chadi Nabhan Oncology Specialists, S.C. Lutheran General Hospital Cancer Care Center Park Ridge Illinois USA
,
David Patton Department of Medicine, Division of Hematology and Oncology Northwestern University Feinberg School of Medicine and Robert H. Lurie Comprehensive Cancer Center Chicago Illinois USA
,
Leo Gordon Department of Medicine, Division of Hematology and Oncology Northwestern University Feinberg School of Medicine and Robert H. Lurie Comprehensive Cancer Center Chicago Illinois USA
,
Mary Riley Department of Medicine, Division of Hematology and Oncology Northwestern University Feinberg School of Medicine and Robert H. Lurie Comprehensive Cancer Center Chicago Illinois USA
,
Timothy Kuzel Department of Medicine, Division of Hematology and Oncology Northwestern University Feinberg School of Medicine and Robert H. Lurie Comprehensive Cancer Center Chicago Illinois USA
,
Martin Tallman Department of Medicine, Division of Hematology and Oncology Northwestern University Feinberg School of Medicine and Robert H. Lurie Comprehensive Cancer Center Chicago Illinois USA
&
Steven Rosen Department of Medicine, Division of Hematology and Oncology Northwestern University Feinberg School of Medicine and Robert H. Lurie Comprehensive Cancer Center Chicago Illinois USA
 show all
Pages 2269-2273 | Published online: 01 Jul 2009

Citations (55)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (17)

Clive S. Zent, Timothy G. Call, Deborah A. Bowen, Michael J. Conte, Betsy R. LaPlant, Thomas E. Witzig, Stephen M. Ansell & George J. Weiner. (2015) Early treatment of high risk chronic lymphocytic leukemia with alemtuzumab, rituximab and poly-(1-6)-beta-glucotriosyl-(1-3)- beta-glucopyranose beta-glucan is well tolerated and achieves high complete remission rates. Leukemia & Lymphoma 56:8, pages 2373-2378.
Read now
Tadeusz Robak. (2014) Current and emerging monoclonal antibody treatments for chronic lymphocytic leukemia: state of the art. Expert Review of Hematology 7:6, pages 841-857.
Read now
Clive S. Zent, Wenting Wu, Deborah A. Bowen, Curtis A. Hanson, Adam M. Pettinger, Tait D. Shanafelt, Neil E. Kay, Jose F. Leis & Timothy G. Call. (2013) Addition of granulocyte macrophage colony stimulating factor does not improve response to early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab. Leukemia & Lymphoma 54:3, pages 476-482.
Read now
Tadeusz Robak, Pawel Robak & Piotr Smolewski. (2012) The evaluation and optimal use of rituximab in lymphoid malignancies. Blood and Lymphatic Cancer: Targets and Therapy 2, pages 1-16.
Read now
Nisar A. Baig, Ronald P. Taylor, Margaret A. Lindorfer, Amy K. Church, Betsy R. Laplant, Emily S. Pavey, Grzegorz S. Nowakowski & Clive S. Zent. (2012) Complement dependent cytotoxicity in chronic lymphocytic leukemia: ofatumumab enhances alemtuzumab complement dependent cytotoxicity and reveals cells resistant to activated complement. Leukemia & Lymphoma 53:11, pages 2218-2227.
Read now
Stéphane Lepretre, Uli Jäger, Ann Janssens, Veronique Leblond, Eugene Nikitin, Tadeusz Robak & Clemens-Martin Wendtner. (2012) The value of rituximab for the treatment of fludarabine-refractory chronic lymphocytic leukemia: a systematic review and qualitative analysis of the literature. Leukemia & Lymphoma 53:5, pages 820-829.
Read now
Tadeusz Robak. (2012) Rituximab for chronic lymphocytic leukemia. Expert Opinion on Biological Therapy 12:4, pages 503-515.
Read now
Aisha Masood, Taimur Sher, Aneel Paulus, Kena C Miller, Kasyapa S Chitta & Asher Chanan-Khan. (2011) Targeted treatment for chronic lymphocytic leukemia. OncoTargets and Therapy 4, pages 169-183.
Read now
Chadi Nabhan, Neil Dalal, Jayesh Mehta & Neil E. Kay. (2011) Biologic agent activity in chronic lymphocytic leukemia: a framework for future therapies. Leukemia & Lymphoma 52:3, pages 374-386.
Read now
Alessandra Tedeschi, Eleonora Vismara, Francesca Ricci, Enrica Morra & Marco Montillo. (2010) The spectrum of use of rituximab in chronic lymphocytic leukemia. OncoTargets and Therapy 3, pages 227-246.
Read now
Aref Al-Kali, William Wierda, Michael Keating & Susan O’Brien. (2010) Critical appraisal of the role of rituximab in the treatment of patients with previously untreated or treated chronic lymphocytic leukemia (CLL). Journal of Blood Medicine 1, pages 115-122.
Read now
Tadeusz Robak, Ewa Lech-Maranda & Pawel Robak. (2010) Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia. Expert Review of Anticancer Therapy 10:10, pages 1529-1543.
Read now
Myron S. Czuczman & Stephanie A. Gregory. (2010) The future of CD20 monoclonal antibody therapy in B-cell malignancies. Leukemia & Lymphoma 51:6, pages 983-994.
Read now
Marco Montillo, Francesca Ricci, Sara Miqueleiz, Alessandra Tedeschi & Enrica Morra. (2008) Alemtuzumab in the treatment of fludarabine refractory B-cell chronic lymphocytic leukemia (CLL). Biologics: Targets and Therapy 2:1, pages 41-52.
Read now
Tadeusz Robak. (2008) Alemtuzumab for B-cell chronic lymphocytic leukemia. Expert Review of Anticancer Therapy 8:7, pages 1033-1051.
Read now
Mohamed A Kharfan-Dabaja, Rabih Fahed, Mohamad Hussein & Edgardo S Santos. (2007) Evolving role of monoclonal antibodies in the treatment of chronic lymphocytic leukemia. Expert Opinion on Investigational Drugs 16:11, pages 1799-1815.
Read now
Alessandra Ferrajoli, Stefan Faderl & Michael J Keating. (2006) Monoclonal antibodies in chronic lymphocytic leukemia. Expert Review of Anticancer Therapy 6:9, pages 1231-1238.
Read now

Articles from other publishers (38)

Yan-Ruide Li, Ying Fang, Zibai Lyu, Yichen Zhu & Lili Yang. (2023) Exploring the dynamic interplay between cancer stem cells and the tumor microenvironment: implications for novel therapeutic strategies. Journal of Translational Medicine 21:1.
Crossref
Liqun Yang, Pengfei Shi, Gaichao Zhao, Jie Xu, Wen Peng, Jiayi Zhang, Guanghui Zhang, Xiaowen Wang, Zhen Dong, Fei Chen & Hongjuan Cui. (2020) Targeting cancer stem cell pathways for cancer therapy. Signal Transduction and Targeted Therapy 5:1.
Crossref
Per Ljungman, Rafael de la Camara, Christine Robin, Roberto Crocchiolo, Hermann Einsele, Joshua A Hill, Petr Hubacek, David Navarro, Catherine Cordonnier & Katherine N Ward. (2019) Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7). The Lancet Infectious Diseases 19:8, pages e260-e272.
Crossref
Clive S. ZentXin Victoria Wang, Rhett P. Ketterling, Curtis A. Hanson, Edward N. Libby, Jacqueline C. Barrientos, Timothy G. Call, Julie E. Chang, Jane J. Liu, Alejandro R. Calvo, Hillard M. Lazarus, Jacob M. Rowe, Selina M. Luger, Mark R. Litzow & Martin S. Tallman. (2016) A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOG-ACRIN cancer research group (E1908). American Journal of Hematology 91:3, pages 308-312.
Crossref
Linda M. Henricks, Jan H.M. Schellens, Alwin D.R. Huitema & Jos H. Beijnen. (2015) The use of combinations of monoclonal antibodies in clinical oncology. Cancer Treatment Reviews 41:10, pages 859-867.
Crossref
Clive S. Zent, Ronald P. Taylor, Margaret A. Lindorfer, Paul V. Beum, Betsy LaPlant, Wenting Wu, Timothy G. Call, Deborah A. Bowen, Michael J. Conte, Lori A. Frederick, Brian K. Link, Sue E. Blackwell, Suresh Veeramani, Nisar A. Baig, David S. Viswanatha, George J. Weiner & Thomas E. Witzig. (2014) Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cells. American Journal of Hematology 89:7, pages 757-765.
Crossref
Amy Grimsley, Katherine S. Shah & Trevor McKibbin. 2013. Pharmaceutical Biotechnology. Pharmaceutical Biotechnology 337 359 .
Jeremy L. Warner & Jon E. Arnason. (2012) Alemtuzumab use in relapsed and refractory chronic lymphocytic leukemia: a history and discussion of future rational use. Therapeutic Advances in Hematology 3:6, pages 375-389.
Crossref
Marays VelizJavier Pinilla-Ibarz. (2012) Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia. Cancer Control 19:1, pages 37-53.
Crossref
Séverine Loisel, Pierre-Alain André, Josee Golay, Franz Buchegger, Jean Kadouche, Martine Cérutti, Luca Bologna, Marek Kosinski, David Viertl, Angelika Bischof Delaloye, Christian Berthou, Jean-Pierre Mach & Laurence Boumsell. (2011) Antitumour effects of single or combined monoclonal antibodies directed against membrane antigens expressed by human B cells leukaemia. Molecular Cancer 10:1.
Crossref
Chadi NabhanNeil E. Kay. (2011) The Emerging Role of Ofatumumab in the Treatment of Chronic Lymphocytic Leukemia. Clinical Medicine Insights: Oncology 5, pages CMO.S4087.
Crossref
André Goy & Susan O’Brien. 2011. Principles and Practice of Cancer Infectious Diseases. Principles and Practice of Cancer Infectious Diseases 47 66 .
David Gómez-Almaguer, Manuel Solano-Genesta, Luz Tarín-Arzaga, José Luis Herrera-Garza, Olga Graciela Cantú-Rodríguez, César Homero Gutiérrez-Aguirre & José Carlos Jaime-Pérez. (2010) Low-dose rituximab and alemtuzumab combination therapy for patients with steroid-refractory autoimmune cytopenias. Blood 116:23, pages 4783-4785.
Crossref
Wei‐Gang Tong & Alessandra Ferrajoli. 2010. Leukemias: Principles and Practice of Therapy. Leukemias: Principles and Practice of Therapy 327 337 .
Karen W. L. Yee & Susan M. O'Brien. 2011. Management of Hematologic Malignancies. Management of Hematologic Malignancies 81 102 .
Susan O'Brien & Anders Österborg. (2010) Ofatumumab: A New CD20 Monoclonal Antibody Therapy for B-Cell Chronic Lymphocytic Leukemia. Clinical Lymphoma Myeloma and Leukemia 10:5, pages 361-368.
Crossref
Margaret T. Kasner. (2010) Novel Targets for Treatment of Adult Acute Lymphocytic Leukemia. Current Hematologic Malignancy Reports 5:4, pages 207-212.
Crossref
Sameer A. Parikh & William G. Wierda. (2010) Role of CD20 Monoclonal Antibodies in Previously Untreated Chronic Lymphocytic Leukemia. Clinical Lymphoma Myeloma and Leukemia 10, pages S27-S33.
Crossref
Marina Motta, William G. Wierda & Alessandra Ferrajoli. (2009) Chronic lymphocytic leukemia. Cancer 115:17, pages 3830-3841.
Crossref
Apostolia-Maria Tsimberidou & Michael J. Keating. (2009) Treatment of fludarabine-refractory chronic lymphocytic leukemia. Cancer 115:13, pages 2824-2836.
Crossref
Mohamed Kharfan-Dabaja & Edgardo Santos. 2009. Emerging Protein Biotherapeutics. Emerging Protein Biotherapeutics.
S Faderl, A Ferrajoli, O Frankfurt & A Pettitt. (2008) Treatment of B-cell chronic lymphocytic leukemia with nonchemotherapeutic agents: experience with single-agent and combination therapy. Leukemia 23:3, pages 457-466.
Crossref
Robert O. Dillman. 2009. Principles of Cancer Biotherapy. Principles of Cancer Biotherapy 303 406 .
Karen Yee, Michael Keating & Susan O’Brien. 2008. Chronic Lymphocytic Leukemia. Chronic Lymphocytic Leukemia 141 164 .
Arun Vijay & Morie A. Gertz. (2008) Current Treatment Options for Waldenström Macroglobulinemia. Clinical Lymphoma and Myeloma 8:4, pages 219-229.
Crossref
P Ljungman, R de la Camara, C Cordonnier, H Einsele, D Engelhard, P Reusser, J Styczynski & K Ward. (2008) Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT. Bone Marrow Transplantation 42:4, pages 227-240.
Crossref
Chadi Nabhan. (2008) First-Line Treatment in Chronic Lymphocytic Leukemia: A Risk-Stratified Approach. Clinical Leukemia 2:2, pages 121-127.
Crossref
Chadi Nabhan, Tait D. Shanafelt & Neil E. Kay. (2008) Controversies in the front-line management of chronic lymphocytic leukemia. Leukemia Research 32:5, pages 679-688.
Crossref
Apostolia-Maria Tsimberidou & Michael J. Keating. 2008. Targeted Cancer Therapy. Targeted Cancer Therapy 61 86 .
Peter Hillmen, Aleksander B. Skotnicki, Tadeusz Robak, Branimir Jaksic, Anna Dmoszynska, Jingyang Wu, Cynthia Sirard & Jiri Mayer. (2007) Alemtuzumab Compared With Chlorambucil As First-Line Therapy for Chronic Lymphocytic Leukemia. Journal of Clinical Oncology 25:35, pages 5616-5623.
Crossref
Peter H. Wiernik. (2006) Plasma cell dyscrasias and leukemias. Update on Cancer Therapeutics 1:4, pages 539-567.
Crossref
Lesley Ann Saketkoo & Luis R. Espinoza. (2006) Impact of Biologic Agents on Infectious Diseases. Infectious Disease Clinics of North America 20:4, pages 931-961.
Crossref
Stefan Faderl, Susan O'Brien & Michael J. Keating. (2006) Monoclonal antibody combinations in CLL: evolving strategies. Best Practice & Research Clinical Haematology 19:4, pages 781-793.
Crossref
Karen W.L. Yee & Susan M. O'Brien. (2006) Chronic Lymphocytic Leukemia: Diagnosis and Treatment. Mayo Clinic Proceedings 81:8, pages 1105-1129.
Crossref
Emili MontserratCarol MorenoJordi EsteveAlvaro Urbano-IspizuaEva GinéFrancesc Bosch. (2006) How I treat refractory CLL. Blood 107:4, pages 1276-1283.
Crossref
Bruce D. Cheson. (2005) Monoclonal antibody therapy of chronic lymphocytic leukemia. Cancer Immunology, Immunotherapy 55:2, pages 188-196.
Crossref
Chadi Nabhan. (2005) The Emerging Role of Alemtuzumab in Chronic Lymphocytic Leukemia. Clinical Lymphoma and Myeloma 6:2, pages 115-121.
Crossref
. (2005) Current Awareness in Hematological Oncology. Hematological Oncology 22:4, pages 183-190.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.